Article Text

PDF
DIRECT PHASE II SBIR GRANTS TO SUPPORT BIOMEDICAL TECHNOLOGY DEVELOPMENT: PAR-14-088

Statistics from Altmetric.com

Components of Participating Organizations

National Institutes of Health

National Center for Advancing Translational Sciences

National Cancer Institute

National Eye Institute

National Human Genome Research Institute

National Heart, Lung, and Blood Institute

National Institute on Aging

National Institute of Allergy and Infectious Diseases

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institute of Biomedical Imaging and Bioengineering

Eunice Kennedy Shriver National Institute of Child Health and Human Development

National Institute on Drug Abuse

National Institute on Deafness and Other Communication Disorders

National Institute of Dental and Craniofacial Research

National Institute of General Medical Sciences

National Institute of Mental Health

National Institute on Minority Health and Health Disparities

National Institute of Neurological Disorders and Stroke

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Application Receipt/Submission Date(s): Multiple dates, see announcement.

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.

Complete details available at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-088.html.

ALZHEIMER’S DISEASE PILOT CLINICAL TRIALS (R01): PAR-14-089

Components of Participating Organizations

National Institute on Aging

Application Receipt/Submission Date(s): Multiple dates, see announcement.

Funding Opportunity Purpose

The objective of the Alzheimer’s Disease Pilot Clinical Trials initiative is to enable the clinical testing (Phase I and II) of promising pharmacological and non-pharmacological interventions in individuals across the Alzheimer’s disease (AD) spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.